NTPDase

Apyrase is a nucleoside triphosphate diphosphohydrolase (NTPDase) that hydrolyzes extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP). This enzymatic activity inhibits the release of Shiga toxin 2 (Stx2) from enterohemorrhagic Escherichia coli (EHEC), thereby providing protection to intestinal barrier function. Apyrase is a valuable tool for investigating mechanisms of infection and inflammation, particularly in studies related to hemorrhagic colitis.

PSB-06126 is a selective inhibitor of nucleoside triphosphate diphosphohydrolase (NTPDase), demonstrating Ki values of 0.33 μM for rat NTPDase 1, 19.1 μM for NTPDase 2, and 2.22 μM for NTPDase 3. In human NTPDase 3, it exhibits an IC50 value of 7.76 μM and a Ki value of 4.39 μM. This compound is useful for studying the role of NTPDases in purinergic signaling and may aid in the exploration of therapeutic strategies targeting related pathological conditions.

PSB-16131 is a potent non-competitive inhibitor of human NTPDase2, exhibiting an IC50 value of 539 nM. This compound is valuable for investigating the roles of NTPDase2 in various biological contexts, including inflammation, neurodegenerative diseases, and cancer research. Its inhibitory effects can facilitate the exploration of biochemical pathways associated with these conditions.

PSB069 is a nonselective inhibitor of NTPDases 1, 2, and 3, featuring a p-chlorophenylamino moiety. With an inhibition constant (Ki) ranging from 16 to 18 μM, this compound exhibits potent activity against these enzymes. PSB069 is valuable for research applications aimed at elucidating the role of NTPDases in various cellular processes and understanding their implications in disease mechanisms.

NTPDase-IN-2 is a selective inhibitor of NTPDase with IC50 values of 0.04 µM for human NTPDase-2 and 2.27 µM for human NTPDase-8. This compound exhibits non-competitive inhibition of NTPDase-1 and NTPDase-2, with a Km of 74 µM for NTPDase-2. NTPDase-IN-2 is suitable for investigating its effects in cancer research, immunologic disorders, and bacterial infections.

h-NTPDase-IN-5 is a pan-inhibitor of NTPDase enzymes, demonstrating IC50 values of 1.10 μM for h-NTPDase1, 44.73 μM for h-NTPDase2, 26.14 μM for h-NTPDase3, and 0.32 μM for h-NTPDase8. This compound effectively modulates ATP metabolism by targeting ecto-nucleotide triphosphate diphosphohydrolases, making it a valuable tool for investigating purinergic signaling pathways. Its inhibitory profile supports research applications in cell signaling, neurobiology, and the study of various pathophysiological conditions related to nucleotide signaling.

NTPDase-IN-3 is a potent inhibitor of NTPDase enzymes, demonstrating IC50 values of 0.05 μM for NTPDase8, 0.38 μM for NTPDase3, 0.21 μM for NTPDase1, and 1.07 μM for NTPDase2. This compound plays a significant role in the regulation of nucleotide signaling pathways and is a valuable tool for research focused on cancer and thrombosis. Its specificity and effectiveness in modulating NTPDase activity make it essential for studies investigating these critical biological processes.

PSB-6426 is a selective inhibitor of human NTPDase2, demonstrating a Ki value of 8.2 μM. This compound has potential applications in stroke and cancer research, where modulation of purinergic signaling may provide therapeutic benefits.

h-NTPDase-IN-3 is a potent pan-inhibitor of NTPDase enzymes, demonstrating varying inhibitory activity with IC50 values of 34.13 μM for h-NTPDase1, 0.33 μM for h-NTPDase2, 23.21 μM for h-NTPDase3, and 2.48 μM for h-NTPDase8. This compound is valuable for research focused on purinergic signaling, offering insights into the regulation of extracellular nucleotide levels. Its ability to inhibit multiple NTPDase isoforms makes it suitable for studies exploring their roles in various physiological and pathological processes.

NTPDase-IN-1 is a selective inhibitor targeting NTPDase enzymes, exhibiting IC50 values of 0.05, 0.23, and 0.54 µM for human NTPDase-1, -2, and -8 respectively. This compound acts as a non-competitive inhibitor for NTPDase-1 and -2, displaying a Km of 21 µM for NTPDase-1. NTPDase-IN-1 is applicable in research focused on cancer, immunological disorders, and bacterial infections.

h-NTPDase8-IN-1 is a selective inhibitor of human NTPDase8, exhibiting an IC50 value of 0.28 μM. This compound, classified as a sulfamoyl-benzamide, plays a crucial role in the modulation of physiological and pathological processes, including thrombosis, diabetes, inflammation, and cancer. Its potent inhibition of h-NTPDase8 makes it a valuable tool for research applications targeting these diverse biological functions.

h-NTPDase-IN-4 is a potent pan-inhibitor of NTPDase, demonstrating IC50 values of 3.58 μM against h-NTPDase1, 10.21 μM against h-NTPDase2, 0.13 μM against h-NTPDase3, and 13.57 μM against h-NTPDase8. This compound selectively modulates nucleotide metabolism and purinergic signaling pathways, making it a valuable tool for research in cellular communication, inflammation, and cancer biology. Its broad activity across multiple NTPDase isoforms positions it as a significant reagent for studies investigating the role of purinergic receptors in various physiological and pathological processes.

TcNTPDase1-IN-1 is a potent inhibitor of nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1) derived from Trypanosoma cruzi. This compound demonstrates key biological activities relevant to antibacterial, antitoxic, and antitumor research applications. By selectively targeting TcNTPDase1, TcNTPDase1-IN-1 provides valuable insights into its role in disease mechanisms and may aid in the development of therapeutic strategies against infections and cancer.